{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:15:11Z","timestamp":1789679711929,"version":"4.0.1"},"reference-count":38,"publisher":"BMJ","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"accepted":{"date-parts":[[2025,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether methylcobalamin could effectively and safely prevent hand-foot syndrome in patients with human epidermal growth factor receptor 2 (HER2) negative early breast cancer receiving adjuvant capecitabine treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Multicentre, double blind, randomised, placebo controlled, phase 3 trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Seven hospitals in China between January 2022 and February 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Women aged 18-75 years with pathologically confirmed HER2 negative early breast cancer who were scheduled to receive adjuvant capecitabine treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Eligible patients were randomly assigned in a 1:1 ratio to receive methylcobalamin at a dose of 0.5 mg orally, three times daily, or a placebo for a maximum of 24 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The primary endpoint was the incidence of grade \u22652 hand-foot syndrome occurring for the first time during capecitabine treatment in the intention-to-treat analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>234 patients were randomly assigned to receive methylcobalamin (n=117) or placebo (n=117) and were included in the intention-to-treat and safety analysis. Grade \u22652 hand-foot syndrome occurred in 17 (14.5%) of 117 patients in the methylcobalamin group and 34 (29.1%) of 117 patients in the placebo group (risk difference \u221214.5%, 95% confidence interval \u221224.9% to \u22124.1%; one sided P value=0.003). The rate of reduction or discontinuation of capecitabine treatment because of hand-foot syndrome was 7.7% (9 of 117) in the methylcobalamin group and 13.7% (16 of 117) in the placebo group (risk difference \u22126.0%, 95% confidence interval \u221213.9% to 1.9%). The two groups showed similar incidence of any other adverse events (88 (75.2%) in the methylcobalamin group and 95 (81.2%) in the placebo group). No methylcobalamin specific adverse events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Oral methylcobalamin significantly lowered the severity of hand-foot syndrome by reducing the incidence of grade \u22652 symptoms without unexpected safety concerns in women with HER2 negative early breast cancer who were receiving adjuvant capecitabine treatment. The findings support the use of methylcobalamin to prevent capecitabine associated severe hand-foot syndrome in this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT05165069\" ext-link-type=\"clintrialgov\">NCT05165069<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmj-2025-084290","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:10:13Z","timestamp":1757589013000},"page":"e084290","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial"],"prefix":"10.1136","volume":"390","clinical-trial-number":[{"clinical-trial-number":"nct05165069","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05165069","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yuan","family":"Xia","sequence":"first","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China"},{"name":"Breast Tumour Centre, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Clinical Research Design Division, Clinical Research Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ling","sequence":"additional","affiliation":[{"name":"Clinical Research Design Division, Clinical Research Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Centre, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Yang","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China"},{"name":"Breast Tumour Centre, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, the First People's Hospital of Zhaoqing, Zhaoqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weige","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zouxiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Research Design Division, Clinical Research Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China"},{"name":"Breast Tumour Centre, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Peking University Shenzhen Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Dongguan People's Hospital, Dongguan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwei","family":"Song","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China"},{"name":"Breast Tumour Centre, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-7497","authenticated-orcid":false,"given":"Chang","family":"Gong","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China"},{"name":"Breast Tumour Centre, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"2025091108050747000_390.sep11_3.e084290.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19323"},{"key":"2025091108050747000_390.sep11_3.e084290.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612645"},{"key":"2025091108050747000_390.sep11_3.e084290.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.23370"},{"key":"2025091108050747000_390.sep11_3.e084290.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00938"},{"key":"2025091108050747000_390.sep11_3.e084290.5","first-page":"494","article-title":"The hand-foot syndrome\u2014a frequent secondary manifestation in antineoplastic chemotherapy","volume":"16","author":"Janusch","year":"2006","journal-title":"Eur J Dermatol"},{"key":"2025091108050747000_390.sep11_3.e084290.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0851-8"},{"key":"2025091108050747000_390.sep11_3.e084290.7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0033"},{"key":"2025091108050747000_390.sep11_3.e084290.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504063321401"},{"key":"2025091108050747000_390.sep11_3.e084290.9","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2022.2098348"},{"key":"2025091108050747000_390.sep11_3.e084290.10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr400"},{"key":"2025091108050747000_390.sep11_3.e084290.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.4587"},{"key":"2025091108050747000_390.sep11_3.e084290.12","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.99.3.132"},{"key":"2025091108050747000_390.sep11_3.e084290.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.005"},{"key":"2025091108050747000_390.sep11_3.e084290.14","doi-asserted-by":"publisher","DOI":"10.1097\/01.cnd.0000211401.19995.a2"},{"key":"2025091108050747000_390.sep11_3.e084290.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.019"},{"key":"2025091108050747000_390.sep11_3.e084290.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2009.12.017"},{"key":"2025091108050747000_390.sep11_3.e084290.17","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90925-8"},{"key":"2025091108050747000_390.sep11_3.e084290.18","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(94)90272-0"},{"key":"2025091108050747000_390.sep11_3.e084290.19","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.6.953"},{"key":"2025091108050747000_390.sep11_3.e084290.20","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020395"},{"key":"2025091108050747000_390.sep11_3.e084290.21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0219"},{"key":"2025091108050747000_390.sep11_3.e084290.22","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2025091108050747000_390.sep11_3.e084290.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.10.2756"},{"key":"2025091108050747000_390.sep11_3.e084290.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.024"},{"key":"2025091108050747000_390.sep11_3.e084290.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01730"},{"key":"2025091108050747000_390.sep11_3.e084290.26","unstructured":"US Food and Drug Administration. Draft Guidance on Diclofenac Sodium October 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_022122.pdf."},{"key":"2025091108050747000_390.sep11_3.e084290.27","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-8-688"},{"key":"2025091108050747000_390.sep11_3.e084290.28","doi-asserted-by":"publisher","DOI":"10.1007\/BF00216925"},{"key":"2025091108050747000_390.sep11_3.e084290.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03159.x"},{"key":"2025091108050747000_390.sep11_3.e084290.30","first-page":"31","article-title":"Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity","volume":"16","author":"Lin","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"2025091108050747000_390.sep11_3.e084290.31","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/424651"},{"key":"2025091108050747000_390.sep11_3.e084290.32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00647"},{"key":"2025091108050747000_390.sep11_3.e084290.33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9859"},{"key":"2025091108050747000_390.sep11_3.e084290.34","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231178686"},{"key":"2025091108050747000_390.sep11_3.e084290.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01203"},{"key":"2025091108050747000_390.sep11_3.e084290.36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2090"},{"key":"2025091108050747000_390.sep11_3.e084290.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.12.004"},{"key":"2025091108050747000_390.sep11_3.e084290.38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1269"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2025-084290","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2025-084290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:05:13Z","timestamp":1757603113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2025-084290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":38,"alternative-id":["10.1136\/bmj-2025-084290"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2025-084290","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]}}}